Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA questions whether tested batches of drug are comparable.
Advertisement

Related Content

Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says
FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says
Amylin Speculation Intensifies: Byetta LAR May Be Delayed
Lilly Snatches ImClone Away From Bristol
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC

Topics

Advertisement
UsernamePublicRestriction

Register

PS068518

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel